Iterion Therapeutics Announces Phase 1 Clinical Trial to Study in Acute Myeloid Leukemia
Iterion Therapeutics announces phase 1 clinical trial.
Iterion welcomes new Chief Operating Officer, Jean Chang
Iterion Therapeutics hires Jean Chang as Chief Operating Officer.
Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors
Iterion Therapeutics confirms safety of tegavivint following completion of enrollment in phase 1/2a expansion study.
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings.